查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553607

母细胞浆细胞样树突状细胞肿瘤市场规模、份额、趋势分析报告：按治疗、最终用途和细分市场预测，2024-2030 年

Blastic Plasmacytoid Dendritic Cell Neoplasm Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunotherapy, Stem Cell Transplantation), By End Use (Hospitals, Specialty Clinics), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

母细胞浆细胞样树突状细胞肿瘤市场成长与趋势：

Grand View Research的最新报告预计，到2030年，母细胞性浆细胞样树突状细胞肿瘤的全球市场规模将达到2.1427亿美元，2024年至2030年的复合年增长率为7.7%。

该市场包括对这种罕见骨髓恶性肿瘤的诊断、治疗和管理至关重要的各种组成部分。

由于诊断方法的改进以及医疗保健提供者和患者意识的提高，BPDCN 的盛行率正在增加。发病率的增加推动了对有效治疗的需求。对 BPDCN 分子和遗传方面的理解取得的重大进展促进了标靶治疗的发展，并且有前景的药物正在临床试验中。

BPDCN在多个地区已被列为罕见疾病，透过扩大市场独占权和税额扣抵等激励措施鼓励对该药物的投资。向个人化医疗的转变正在加强基于基因图谱的治疗策略并扩大客製化治疗市场。

母细胞浆细胞样树突状细胞肿瘤市场报告亮点

  • 以治疗方式来看，化疗将占据市场主导地位，到 2023 年，其销售份额将达到 38.7%。化疗与 tagraxofusp 等新药的结合正在彻底改变 BPDCN 的治疗。这凸显了化疗的关键作用，并透过改善治疗结果和引入标靶治疗来推动市场成长。
  • 根据最终用途，医院主导市场，2023 年收益占有率最大，为 57.5%。 BPDCN 盛行率不断上升，在美国和欧洲估计每年有 1,000 至 1,400 例病例，导致医院就诊人数增加。先进的诊断工具和肿瘤学专业化促进了及时、准确的诊断，这对于有效开始治疗至关重要。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章 母细胞浆细胞样树突状细胞肿瘤市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • Blast 浆细胞样树突状细胞肿瘤市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第 4 章 母细胞浆细胞样树突状细胞肿瘤市场：依治疗方法估算与趋势分析

  • 全球母细胞浆细胞样树突状细胞肿瘤市场：治疗仪表板
  • 全球母细胞性浆细胞样树突状细胞肿瘤市场：治疗差异分析
  • 按治疗分類的收益
  • 化疗
  • 免疫疗法
  • 干细胞移植
  • 标靶治疗
  • 其他的

第五章母细胞浆细胞样树突状细胞肿瘤市场：依最终用途的估计与趋势分析

  • 全球母细胞浆细胞样树突状细胞肿瘤市场：依最终用途分類的仪表板
  • 全球母细胞浆细胞样树突状细胞肿瘤市场：最终用途的变异分析
  • 按最终用途分類的收益
  • 医院
  • 专科诊所
  • 其他的

第 6 章 母细胞浆细胞样树突状细胞肿瘤市场：按治疗和最终用途进行的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第七章 竞争格局

  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 2023年主要企业市场占有率分析
    • AbbVie Inc.
    • ImmunoGen, Inc.
    • Mustang Bio
    • Genentech, Inc.
    • Stemline Therapeutics, Inc.
    • Jazz Pharmaceuticals, Inc.
    • Cellex Patient Treatment GmbH
    • Xencor
    • Resverlogix
Product Code: GVR-4-68040-427-8

Blastic Plasmacytoid Dendritic Cell Neoplasm Market Growth & Trends:

The global blastic plasmacytoid dendritic cell neoplasm market size is anticipated to reach USD 214.27 million by 2030 and is projected to grow at a CAGR of 7.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market encompasses a range of elements critical to diagnosing, treating, and managing this rare hematological malignancy.

The incidence of BPDCN is increasing, attributed to better diagnostic methods and heightened awareness among healthcare providers and patients. This rise in incidence boosts the demand for effective treatments. Significant advancements in understanding BPDCN's molecular and genetic aspects led to the development of targeted therapies, with promising drugs undergoing clinical trials.

BPDCN is classified as an orphan disease in various regions, encouraging pharmaceutical investment through incentives such as extended market exclusivity and tax credits. The shift towards personalized medicine enhances treatment strategies based on genetic profiles, expanding the market for customized therapies.

Blastic Plasmacytoid Dendritic Cell Neoplasm Market Report Highlights:

  • Based on treatment, Chemotherapy dominated the market with the largest revenue share of 38.7% in 2023. Combining chemotherapy with novel agents such as tagraxofusp transforms BPDCN treatment. This highlights chemotherapy's pivotal role and drives market growth through improved outcomes and the introduction of targeted therapies.
  • Based on end use, hospitals dominated the market with the largest revenue share of 57.5% in 2023. The rising incidence of BPDCN, estimated at 1,000 to 1,400 cases annually in the U.S. and Europe, increased hospital visits. Advanced diagnostic tools and specialized oncology departments facilitate timely and accurate diagnoses essential for effective treatment initiation.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment Outlook
    • 2.2.2. End Use Outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Blastic Plasmacytoid Dendritic Cell Neoplasm Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing incidence rates of BPDCN
      • 3.2.1.2. Advancements in treatment options
      • 3.2.1.3. Growing awareness and diagnosis of rare hematological malignancies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Limited treatment option
      • 3.2.2.2. Challenges in diagnosis
  • 3.3. Blastic Plasmacytoid Dendritic Cell Neoplasm Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Blastic Plasmacytoid Dendritic Cell Neoplasm Market: Treatment Estimates & Trend Analysis

  • 4.1. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market: Treatment Dashboard
  • 4.2. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market: Treatment Movement Analysis
  • 4.3. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market by Treatment, Revenue
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Immunotherapy
    • 4.5.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Stem Cell Transplantation
    • 4.6.1. Stem cell transplantation market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Targeted Therapy
    • 4.7.1. Targeted therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Other
    • 4.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Blastic Plasmacytoid Dendritic Cell Neoplasm Market: End Use Estimates & Trend Analysis

  • 5.1. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market: End Use Dashboard
  • 5.2. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market: End Use Movement Analysis
  • 5.3. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market Estimates and Forecasts, By End Use, Revenue (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Specialty Clinics
    • 5.5.1. Specialty Clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Other
    • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Blastic Plasmacytoid Dendritic Cell Neoplasm Market: Regional Estimates & Trend Analysis by Treatments, and End Use

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company/Competition Categorization
  • 7.2. Vendor Landscape
    • 7.2.1. List of key distributors and channel partners
    • 7.2.2. Key company market share analysis, 2023
    • 7.2.3. AbbVie Inc.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. ImmunoGen, Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Mustang Bio
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Genentech, Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Stemline Therapeutics, Inc.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Jazz Pharmaceuticals, Inc.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Cellex Patient Treatment GmbH
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Xencor
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. Resverlogix
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Blastic plasmacytoid dendritic cell neoplasm market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 4 North America Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 5 U.S. Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 6 U.S. Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 8 Canada Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Mexico Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 Mexico Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe Blastic plasmacytoid dendritic cell neoplasm market, by region, 2018 - 2030 (USD Million)
  • Table 12 Europe Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 13 Europe Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 14 Germany Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 15 Germany Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 16 UK Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 UK Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 18 France Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 19 France Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Italy Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 21 Italy Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Spain Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 23 Spain Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Denmark Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 25 Denmark Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Sweden Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 27 Sweden Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Norway Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 29 Norway Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Blastic plasmacytoid dendritic cell neoplasm market, by region, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 33 China Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 34 China Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 35 Japan Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 36 Japan Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 37 India Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 India Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 39 South Korea Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 40 South Korea Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Australia Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 42 Australia Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Thailand Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 44 Thailand Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 45 Latin America Blastic plasmacytoid dendritic cell neoplasm market, by region, 2018 - 2030 (USD Million)
  • Table 46 Latin America Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 47 Latin America Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Brazil Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 49 Brazil Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 50 Argentina Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 51 Argentina Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 52 MEA Blastic plasmacytoid dendritic cell neoplasm market, by region, 2018 - 2030 (USD Million)
  • Table 53 MEA Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 54 MEA Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 55 South Africa Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 56 South Africa Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 59 UAE Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 60 UAE Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
  • Table 62 Kuwait Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modeling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Blastic plasmacytoid dendritic cell neoplasm market: market outlook
  • Fig. 7 Blastic plasmacytoid dendritic cell neoplasm competitive insights
  • Fig. 8 Parent market outlook
  • Fig. 9 Related/ancillary market outlook
  • Fig. 10 Blastic plasmacytoid dendritic cell neoplasm market driver impact
  • Fig. 11 Blastic plasmacytoid dendritic cell neoplasm market restraint impact
  • Fig. 12 Blastic plasmacytoid dendritic cell neoplasm market: Treatment movement analysis
  • Fig. 13 Blastic plasmacytoid dendritic cell neoplasm market: Treatment outlook and key takeaways
  • Fig. 14 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Stem cell transplantation market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Blastic plasmacytoid dendritic cell neoplasm market: End Use movement analysis
  • Fig. 20 Blastic plasmacytoid dendritic cell neoplasm market: End Use outlook and key takeaways
  • Fig. 21 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Specialty Clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Global blastic plasmacytoid dendritic cell neoplasm market: Regional movement analysis
  • Fig. 25 Global blastic plasmacytoid dendritic cell neoplasm market: Regional outlook and key takeaways
  • Fig. 26 Global blastic plasmacytoid dendritic cell neoplasm market share and leading players
  • Fig. 27 North America, by country
  • Fig. 28 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. key country dynamics
  • Fig. 30 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Canada key country dynamics
  • Fig. 32 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Mexico key country dynamics
  • Fig. 34 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 UK key country dynamics
  • Fig. 37 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Germany key country dynamics
  • Fig. 39 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 France key country dynamics
  • Fig. 41 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Italy key country dynamics
  • Fig. 43 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Spain key country dynamics
  • Fig. 45 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Denmark key country dynamics
  • Fig. 47 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Sweden key country dynamics
  • Fig. 49 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Norway key country dynamics
  • Fig. 51 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 China key country dynamics
  • Fig. 54 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Japan key country dynamics
  • Fig. 56 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 India key country dynamics
  • Fig. 58 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Thailand key country dynamics
  • Fig. 60 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 South Korea key country dynamics
  • Fig. 62 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Australia key country dynamics
  • Fig. 64 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Brazil key country dynamics
  • Fig. 67 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Argentina key country dynamics
  • Fig. 69 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 South Africa key country dynamics
  • Fig. 72 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia key country dynamics
  • Fig. 74 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 UAE key country dynamics
  • Fig. 76 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Kuwait key country dynamics
  • Fig. 78 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Market share of key market players - Blastic Plasmacytoid Dendritic Cell Neoplasm market